The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Bhatt Elizabeth | President and COO | Option exercise(M) | 4K | — | $0 |
| Jul 15, 2026 | Bhatt Elizabeth | President and COO | Sell(S) | 4K | $33.99 | $136K |
| Jul 15, 2026 | Bhatt Elizabeth | President and COO | Option exercise(M) | 4K | $6.81 | $27K |
| Jul 1, 2026 | Long Daniel D. | SVP, Drug Discovery | Option exercise(M) | 3K | — | $0 |
| Jul 1, 2026 | Long Daniel D. | SVP, Drug Discovery | Sell(S) | 1K | $34.81 | $43K |
| Jul 1, 2026 | Long Daniel D. | SVP, Drug Discovery | Sell(S) | 2K | $34.10 | $72K |
| Jul 1, 2026 | Long Daniel D. | SVP, Drug Discovery | Option exercise(M) | 3K | $2.76 | $9K |
| Jun 29, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 2K | — | $0 |
| Jun 29, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 2K | $35.18 | $77K |
| Jun 29, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 2K | $6.81 | $15K |
| Jun 26, 2026 | Tong Jeffrey K | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2026 | Simson Jake | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2026 | Sharp Shalini | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2026 | Ra Capital Management, L.P. | Director, 10% Owner | Grant(A) | 15K | — | $0 |
| Jun 26, 2026 | Gottesdiener Keith Michael | Director | Grant(A) | 11K | — | $0 |
| Jun 26, 2026 | Ezekowitz Alan | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2026 | Coulie Bernard | Director | Grant(A) | 15K | — | $0 |
| Jun 26, 2026 | Bassan Abraham | Director | Grant(A) | 15K | — | $0 |
| Jun 22, 2026 | Long Daniel D. | SVP, Drug Discovery | Option exercise(M) | 4K | — | $0 |
| Jun 22, 2026 | Long Daniel D. | SVP, Drug Discovery | Option exercise(M) | 11K | — | $0 |
| Jun 22, 2026 | Long Daniel D. | SVP, Drug Discovery | Sell(S) | 7K | $35.97 | $252K |
| Jun 22, 2026 | Long Daniel D. | SVP, Drug Discovery | Sell(S) | 8K | $35.10 | $281K |
| Jun 22, 2026 | Long Daniel D. | SVP, Drug Discovery | Option exercise(M) | 4K | $11.70 | $52K |
| Jun 22, 2026 | Long Daniel D. | SVP, Drug Discovery | Option exercise(M) | 11K | $2.76 | $29K |
| Jun 12, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 6K | — | $0 |
| Jun 12, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 6K | $35.08 | $219K |
| Jun 12, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 6K | $11.70 | $73K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 4K | $1.55 | $7K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 943 | $2.76 | $3K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 637 | $2.76 | $2K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 2K | $27.78 | $47K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 1K | $28.79 | $39K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 3K | $29.66 | $86K |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 4K | — | $0 |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 943 | — | $0 |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 637 | — | $0 |
| May 26, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 12K | — | $0 |
| May 26, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 12K | $30.06 | $355K |
| May 26, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 12K | $6.81 | $80K |
| Apr 15, 2026 | Bhatt Elizabeth | President and COO | Option exercise(M) | 4K | — | $0 |
| Apr 15, 2026 | Bhatt Elizabeth | President and COO | Sell(S) | 326 | $25.86 | $8K |
| Apr 15, 2026 | Bhatt Elizabeth | President and COO | Sell(S) | 1K | $25.24 | $28K |
| Apr 15, 2026 | Bhatt Elizabeth | President and COO | Sell(S) | 3K | $23.76 | $61K |
| Apr 15, 2026 | Bhatt Elizabeth | President and COO | Option exercise(M) | 4K | $6.81 | $27K |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 66K | $28.14 | $1.9M |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Sell(S) | 4K | $27.51 | $113K |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 5K | $2.76 | $14K |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 12K | $2.76 | $32K |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 54K | $1.55 | $83K |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 54K | — | $0 |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 5K | — | $0 |
| Mar 2, 2026 | Shaikhly Samira | Chief People Officer | Option exercise(M) | 12K | — | $0 |
| Feb 18, 2026 | Bhatt Elizabeth | President and COO | Sell(S) | 2K | $29.58 | $53K |
| Feb 18, 2026 | Bhatt Elizabeth | President and COO | Sell(S) | 2K | $28.46 | $63K |
| Feb 18, 2026 | Bhatt Elizabeth | President and COO | Option exercise(M) | 4K | $6.81 | $27K |
| Feb 18, 2026 | Bhatt Elizabeth | President and COO | Option exercise(M) | 4K | — | $0 |
| Feb 6, 2026 | Wilson Mark Andrew | Chief Legal Officer | Grant(A) | 165K | — | $0 |
| Feb 6, 2026 | Finer Jeffrey | Chief Executive Officer, Director | Grant(A) | 400K | — | $0 |
| Feb 6, 2026 | Bhatt Elizabeth | President and COO | Grant(A) | 155K | — | $0 |
| Feb 6, 2026 | Kim Jae B. | Chief Medical Officer | Grant(A) | 125K | — | $0 |
| Feb 6, 2026 | Labrucherie Gil M | Chief Financial Officer | Grant(A) | 125K | — | $0 |
| Feb 6, 2026 | Shaikhly Samira | Chief People Officer | Grant(A) | 80K | — | $0 |
| Feb 6, 2026 | Klein Uwe | SVP, Biological Sciences | Grant(A) | 80K | — | $0 |
| Feb 6, 2026 | Long Daniel D. | SVP, Drug Discovery | Grant(A) | 80K | — | $0 |
| Nov 10, 2025 | Long Daniel D. | SVP, Drug Discovery | Sell(S) | 4K | $18.06 | $63K |
| Sep 25, 2025 | Gottesdiener Keith Michael | Director | Grant(A) | 33K | — | $0 |
| Aug 18, 2025 | Klein Uwe | SVP, Biological Sciences | Option exercise(M) | 10K | $2.76 | $29K |
| Aug 18, 2025 | Klein Uwe | SVP, Biological Sciences | Option exercise(M) | 8K | $6.81 | $52K |
| Aug 18, 2025 | Klein Uwe | SVP, Biological Sciences | Option exercise(M) | 5K | $2.76 | $14K |
| Aug 18, 2025 | Klein Uwe | SVP, Biological Sciences | Option exercise(M) | 5K | — | $0 |
| Aug 18, 2025 | Klein Uwe | SVP, Biological Sciences | Option exercise(M) | 8K | — | $0 |
| Aug 18, 2025 | Klein Uwe | SVP, Biological Sciences | Option exercise(M) | 10K | — | $0 |
| Aug 7, 2025 | Klein Uwe | SVP, Biological Sciences | Grant(A) | 30K | — | $0 |
| Aug 7, 2025 | Long Daniel D. | SVP, Drug Discovery | Grant(A) | 30K | — | $0 |
| Aug 7, 2025 | Finer Jeffrey | Chief Executive Officer, Director | Grant(A) | 210K | — | $0 |
| Aug 7, 2025 | Labrucherie Gil M | Chief Financial Officer | Grant(A) | 38K | — | $0 |
| Aug 7, 2025 | Kim Jae B. | Chief Medical Officer | Grant(A) | 55K | — | $0 |
| Aug 7, 2025 | Bhatt Elizabeth | President and COO | Grant(A) | 95K | — | $0 |
| Aug 7, 2025 | Shaikhly Samira | Chief People Officer | Grant(A) | 30K | — | $0 |
| Jun 17, 2025 | Ezekowitz Alan | Director | Grant(A) | 17K | — | $0 |
| Jun 17, 2025 | Bassan Abraham | Director | Grant(A) | 17K | — | $0 |
| Jun 17, 2025 | Simson Jake | Director | Grant(A) | 17K | — | $0 |
| Jun 17, 2025 | Coulie Bernard | Director | Grant(A) | 17K | — | $0 |
| Jun 17, 2025 | Tong Jeffrey K | Director | Grant(A) | 17K | — | $0 |
| Jun 17, 2025 | Sharp Shalini | Director | Grant(A) | 17K | — | $0 |
| Jun 17, 2025 | RA Capital Healthcare Fund LP | Director, 10% Owner | Grant(A) | 17K | — | $0 |
| Apr 3, 2025 | Finer Jeffrey | CEO and President, Director | Option exercise(M) | 5K | $2.76 | $14K |
| Apr 3, 2025 | Finer Jeffrey | CEO and President, Director | Option exercise(M) | 5K | — | $0 |
| Apr 2, 2025 | Finer Jeffrey | CEO and President, Director | Option exercise(M) | 50K | $2.76 | $138K |
| Apr 2, 2025 | Finer Jeffrey | CEO and President, Director | Option exercise(M) | 50K | — | $0 |
| Mar 7, 2025 | Ezekowitz Alan | Director | Buy(P) | 13K | $6.93 | $92K |
| Mar 6, 2025 | Ezekowitz Alan | Director | Buy(P) | 41K | $6.00 | $248K |
| Mar 5, 2025 | Ezekowitz Alan | Director | Buy(P) | 38K | $5.82 | $220K |
| Mar 4, 2025 | Ezekowitz Alan | Director | Buy(P) | 7K | $6.35 | $48K |
| Feb 27, 2025 | Labrucherie Gil M | Chief Financial Officer | Buy(P) | 4K | $5.85 | $22K |
| Feb 27, 2025 | Finer Jeffrey | CEO and President, Director | Buy(P) | 3K | $5.80 | $17K |
| Feb 26, 2025 | Finer Jeffrey | CEO and President, Director | Buy(P) | 4K | $5.70 | $23K |
| Feb 25, 2025 | Labrucherie Gil M | Chief Financial Officer | Buy(P) | 6K | $5.59 | $35K |
| Feb 25, 2025 | Finer Jeffrey | CEO and President, Director | Buy(P) | 10K | $5.68 | $57K |
| Feb 24, 2025 | Third Rock Ventures GP V, LP | 10% Owner | Buy(P) | 19K | $6.00 | $113K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-01-04 → 2026-07-21. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).